Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis

Modulation by treatment with anti-ICAM-1 correlates with clinical benefit

H. Schulze-Koops, P. E. Lipsky, A. F. Kavanaugh, L. S. Davis

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

The current studies examined whether cytokine patterns indicative of an imbalance in Th1 and Th2 cells could be identified in PBMC of patients with active rheumatoid arthritis (RA). To investigate this possibility, a reproducible PCR technique to assess cytokine mRNA levels in PBMC was employed that minimized in vitro manipulation of the cells. Seven of 14 RA patients had increased mRNA levels for IL-2, 5/14 for IFN-γ, 3/14 for IL-4, and 4/14 for the IL-2R α-chain, compared with normal donors. Whereas 4 patients had elevated mRNA for IL-2 and IFN-γ, indicative of an increase in activated Th1 or Th0 cells, 1 of 14 patients expressed low levels of IL-2 and IFN-γ and high levels of IL-4 mRNA. Seven RA patients were treated with a mAb to ICAM-1 (CD54). To determine whether changes in cytokine mRNA levels might be associated with and/or account for the anti-inflammatory effect of anti-ICAM-1 mAb therapy, changes in cytokine mRNA levels were assessed and correlated with clinical improvement. Anti-ICAM-1 mAb administration was followed by a prompt and transient increase of IFN-γ mRNA. Elevation of IFN- γ mRNA expression throughout the treatment period reflected a temporary increase in the number of circulating CD3+CD4+ T cells, suggestive of altered circulatory patterns of activated Th1-like cells and was related to clinical efficacy. The results indicate that elevated cytokine mRNA levels characteristic for Th1 cells can be detected in the PBMC in active RA and, furthermore, that anti-ICAM-1 mAb may be beneficial in RA by altering the recruitment of activated Th1-like cells into the synovium. This assumption further strengthens the hypothesis of a significant contribution of Th1-like cells to the pathogenesis of RA.

Original languageEnglish (US)
Pages (from-to)5029-5037
Number of pages9
JournalJournal of Immunology
Volume155
Issue number10
StatePublished - 1995

Fingerprint

Intercellular Adhesion Molecule-1
Rheumatoid Arthritis
Cytokines
Th1 Cells
Messenger RNA
Interleukin-4
Interleukin-2
Therapeutics
Th2 Cells
Synovial Membrane
Interleukin-5
Anti-Inflammatory Agents
Tissue Donors
T-Lymphocytes
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Immunology

Cite this

Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis : Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. / Schulze-Koops, H.; Lipsky, P. E.; Kavanaugh, A. F.; Davis, L. S.

In: Journal of Immunology, Vol. 155, No. 10, 1995, p. 5029-5037.

Research output: Contribution to journalArticle

@article{7ea28bb73410462aa7bf55f441c50aa4,
title = "Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis: Modulation by treatment with anti-ICAM-1 correlates with clinical benefit",
abstract = "The current studies examined whether cytokine patterns indicative of an imbalance in Th1 and Th2 cells could be identified in PBMC of patients with active rheumatoid arthritis (RA). To investigate this possibility, a reproducible PCR technique to assess cytokine mRNA levels in PBMC was employed that minimized in vitro manipulation of the cells. Seven of 14 RA patients had increased mRNA levels for IL-2, 5/14 for IFN-γ, 3/14 for IL-4, and 4/14 for the IL-2R α-chain, compared with normal donors. Whereas 4 patients had elevated mRNA for IL-2 and IFN-γ, indicative of an increase in activated Th1 or Th0 cells, 1 of 14 patients expressed low levels of IL-2 and IFN-γ and high levels of IL-4 mRNA. Seven RA patients were treated with a mAb to ICAM-1 (CD54). To determine whether changes in cytokine mRNA levels might be associated with and/or account for the anti-inflammatory effect of anti-ICAM-1 mAb therapy, changes in cytokine mRNA levels were assessed and correlated with clinical improvement. Anti-ICAM-1 mAb administration was followed by a prompt and transient increase of IFN-γ mRNA. Elevation of IFN- γ mRNA expression throughout the treatment period reflected a temporary increase in the number of circulating CD3+CD4+ T cells, suggestive of altered circulatory patterns of activated Th1-like cells and was related to clinical efficacy. The results indicate that elevated cytokine mRNA levels characteristic for Th1 cells can be detected in the PBMC in active RA and, furthermore, that anti-ICAM-1 mAb may be beneficial in RA by altering the recruitment of activated Th1-like cells into the synovium. This assumption further strengthens the hypothesis of a significant contribution of Th1-like cells to the pathogenesis of RA.",
author = "H. Schulze-Koops and Lipsky, {P. E.} and Kavanaugh, {A. F.} and Davis, {L. S.}",
year = "1995",
language = "English (US)",
volume = "155",
pages = "5029--5037",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "10",

}

TY - JOUR

T1 - Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis

T2 - Modulation by treatment with anti-ICAM-1 correlates with clinical benefit

AU - Schulze-Koops, H.

AU - Lipsky, P. E.

AU - Kavanaugh, A. F.

AU - Davis, L. S.

PY - 1995

Y1 - 1995

N2 - The current studies examined whether cytokine patterns indicative of an imbalance in Th1 and Th2 cells could be identified in PBMC of patients with active rheumatoid arthritis (RA). To investigate this possibility, a reproducible PCR technique to assess cytokine mRNA levels in PBMC was employed that minimized in vitro manipulation of the cells. Seven of 14 RA patients had increased mRNA levels for IL-2, 5/14 for IFN-γ, 3/14 for IL-4, and 4/14 for the IL-2R α-chain, compared with normal donors. Whereas 4 patients had elevated mRNA for IL-2 and IFN-γ, indicative of an increase in activated Th1 or Th0 cells, 1 of 14 patients expressed low levels of IL-2 and IFN-γ and high levels of IL-4 mRNA. Seven RA patients were treated with a mAb to ICAM-1 (CD54). To determine whether changes in cytokine mRNA levels might be associated with and/or account for the anti-inflammatory effect of anti-ICAM-1 mAb therapy, changes in cytokine mRNA levels were assessed and correlated with clinical improvement. Anti-ICAM-1 mAb administration was followed by a prompt and transient increase of IFN-γ mRNA. Elevation of IFN- γ mRNA expression throughout the treatment period reflected a temporary increase in the number of circulating CD3+CD4+ T cells, suggestive of altered circulatory patterns of activated Th1-like cells and was related to clinical efficacy. The results indicate that elevated cytokine mRNA levels characteristic for Th1 cells can be detected in the PBMC in active RA and, furthermore, that anti-ICAM-1 mAb may be beneficial in RA by altering the recruitment of activated Th1-like cells into the synovium. This assumption further strengthens the hypothesis of a significant contribution of Th1-like cells to the pathogenesis of RA.

AB - The current studies examined whether cytokine patterns indicative of an imbalance in Th1 and Th2 cells could be identified in PBMC of patients with active rheumatoid arthritis (RA). To investigate this possibility, a reproducible PCR technique to assess cytokine mRNA levels in PBMC was employed that minimized in vitro manipulation of the cells. Seven of 14 RA patients had increased mRNA levels for IL-2, 5/14 for IFN-γ, 3/14 for IL-4, and 4/14 for the IL-2R α-chain, compared with normal donors. Whereas 4 patients had elevated mRNA for IL-2 and IFN-γ, indicative of an increase in activated Th1 or Th0 cells, 1 of 14 patients expressed low levels of IL-2 and IFN-γ and high levels of IL-4 mRNA. Seven RA patients were treated with a mAb to ICAM-1 (CD54). To determine whether changes in cytokine mRNA levels might be associated with and/or account for the anti-inflammatory effect of anti-ICAM-1 mAb therapy, changes in cytokine mRNA levels were assessed and correlated with clinical improvement. Anti-ICAM-1 mAb administration was followed by a prompt and transient increase of IFN-γ mRNA. Elevation of IFN- γ mRNA expression throughout the treatment period reflected a temporary increase in the number of circulating CD3+CD4+ T cells, suggestive of altered circulatory patterns of activated Th1-like cells and was related to clinical efficacy. The results indicate that elevated cytokine mRNA levels characteristic for Th1 cells can be detected in the PBMC in active RA and, furthermore, that anti-ICAM-1 mAb may be beneficial in RA by altering the recruitment of activated Th1-like cells into the synovium. This assumption further strengthens the hypothesis of a significant contribution of Th1-like cells to the pathogenesis of RA.

UR - http://www.scopus.com/inward/record.url?scp=0028972559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028972559&partnerID=8YFLogxK

M3 - Article

VL - 155

SP - 5029

EP - 5037

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 10

ER -